Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,741,995
  • Shares Outstanding, K 75,937
  • Annual Sales, $ 10,680 K
  • Annual Income, $ -98,150 K
  • 60-Month Beta 1.80
  • Price/Sales 149.81
  • Price/Cash Flow N/A
  • Price/Book 6.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.38
  • Number of Estimates 7
  • High Estimate -0.29
  • Low Estimate -0.45
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.75 +48.48%
on 03/13/20
28.04 -11.29%
on 03/19/20
-4.59 (-15.58%)
since 03/06/20
3-Month
16.75 +48.48%
on 03/13/20
32.39 -23.22%
on 03/03/20
+5.06 (+25.54%)
since 01/06/20
52-Week
12.59 +97.54%
on 11/06/19
32.39 -23.22%
on 03/03/20
+6.68 (+36.72%)
since 04/05/19

Most Recent Stories

More News
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

FATE : 24.36 (+6.19%)
ALEC : 23.25 (+6.16%)
Tesla, Dave & Buster rise; Chewy, Macquarie fall

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Friday:

XOM : 39.92 (+1.81%)
LEG : 25.37 (+11.66%)
LULU : 194.12 (+7.10%)
FATE : 24.36 (+6.19%)
CHWY : 33.96 (+1.77%)
TSLA : 507.83 (+5.80%)
JNJ : 137.66 (+2.60%)
MIC : 19.57 (+7.23%)
Fate Therapeutics Surges on Immunotherapy Deal With J&J

Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company....

JNJ : 137.66 (+2.60%)
CELG : 108.24 (+0.10%)
BMY : 57.28 (+3.15%)
FATE : 24.36 (+6.19%)
Thinking about buying stock in Aytu Bioscience, Citigroup, Chewy, Fate Therapeutics, or General Electric?

InvestorsObserver issues critical PriceWatch Alerts for AYTU, C, CHWY, FATE, and GE.

AYTU : 1.5800 (-2.47%)
C : 40.28 (+7.44%)
FATE : 24.36 (+6.19%)
GE : 7.13 (+5.94%)
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

ê?· Collaboration leverages Company's iPSC product platform and Janssen's proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ê?·

FATE : 24.36 (+6.19%)
Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that...

FATE : 24.36 (+6.19%)
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?

Investors need to pay close attention to Fate Therapeutics (FATE) stock based on the movements in the options market lately.

FATE : 24.36 (+6.19%)
The FATE Paradox: Analysts Bullish But Forecast -12.43% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Fate Therapeutics Inc . The average 12-month price target for FATE — averaging the work...

FATE : 24.36 (+6.19%)
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 5.13% and 52.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

FATE : 24.36 (+6.19%)
Fate Therapeutics: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $28.3 million in its fourth quarter.

FATE : 24.36 (+6.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FATE with:

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

2nd Resistance Point 25.97
1st Resistance Point 24.46
Last Price 24.36
1st Support Level 21.97
2nd Support Level 20.99

See More

52-Week High 32.39
Fibonacci 61.8% 24.83
Last Price 24.36
Fibonacci 50% 22.49
Fibonacci 38.2% 20.15
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar